# A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin

> **NCT01624025** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Advanced Gastric Cancer

## Interventions

- **OTHER:** Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

## Key facts

- **NCT ID:** NCT01624025
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-09
- **Final completion:** 2016-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624025, "A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01624025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*